Original Research

Original Research

  1. 1. The Do-It-Yourself Artificial Pancreas: A Comprehensive Review. Kesavadev J, Srinivasan S, Saboo B, Krishna M. B, Krishnan G. Diabetes Ther. 2020. Link 1| Link 2
  2. 2. Real-world Data Reveal Unmet Clinical Needs in Insulin Treatment in Asian People With Type 2 Diabetes: The Joint Asia Diabetes Evaluation (JADE) Register. Kong A. P. S, Lew T, Lau E. S. H, Lim L. L, Kesavadev J, Jia W, Sheu W H-H, Sobrepena L, Tan A. T. B, Nguyen T. K, Yoon K. H, Wang K, Kodiappan K, Treuer T, Chan J. C. N, JADE Collaborative Study Group. Diabetes Obes Metab. 2020 Apr;22(4):669-679. Link 1| Link 2
  3. 3. Newer insulins on the horizon. Kesavadev J, Ramachandran L. RSSDI’s INSULIN Monograph (A Complete Guide to Insulin Therapy). Jaypee Brothers Medical Publishers (P) Ltd. 2020. 138-143. Read More
  4. 4. Inertia for the Use of Technological Advances for Effective Diabetes Management. Kesavadev J. Int J Diab 2019.1-2. Editorial. Read More
  5. 5. Pathophysiology of Type 2 Diabetes. Kesavadev J, Jawad F, Deeb A, Coetzee A, Jalil Ansari M. A, Shrestha D, Somasundaram N, Kalra S. The Diabetes Textbook. Springer. 2019. 101-116. Read More
  6. 6. Unproven Therapies for Diabetes. Kesavadev J, Ramachandran L, Kalra, S. The Diabetes Textbook. Springer. 2019. 999-1013. Read More
  7. 7. Exploratory CSII Randomized Controlled Trial on Erectile Dysfunction in T2DM Patients (ECSIITED). Kesavadev J, Pillai P. B. S, Shankar A, Warrier R. S, Ramachandran L, Jothydev S, Krishnan G. J Diabetes Sci Technol. 2018. 12(6). 1252–1253.
    Read More
  8. 8. Our First 825 T2DM Patients on 14-Day Factory-Calibrated Glucose Monitoring System: Clinical Utility and Challenges. Kesavadev J, Shankar A, Ashok A.D, Srinivas S, Ajai N. A, Sanal G, Krishnan G, Ramachandran L, Jothydev S. J Diabetes Sci Technol. 2018. 12(1). 230–231. Read More
  9. 9. Consensus recommendations on exploring effective solutions for the rising cost of diabetes. Sadikot S. M, Das A. K, Wilding J, Siyan A, Zargar A. H, Saboo B, Aravind S. R, Sosale B, Kalra S, Vijayakumar G, Manojan K. K, Maheshwari A, Panda J. K, Banerjee S, Chawla R, Vasudevan S. P, Sundar O. S. S, Kesavadev J. Diabetes Metab Syndr. 2017. 11(2). 141-147. Read More
  10. 10. Efficacy and safety concerns regarding Complementary and Alternative Medicine use among diabetes patients. Kesavadev J. J Pak Med Assoc. 2017. 67(2). 316-319. Read More
  11. 11. Unproven Therapies for Diabetes and Their Implications. Kesavadev J, Saboo B, Sadikot S, Das A. K, Joshi S, Chawla R, Thacker H, Shankar A, Ramachandran L, Kalra S. Adv Ther. 2017. 34(1). 60-77. Read More
  12. 12. Sitagliptin 100 mg vs glimepiride 1–3 mg as an add-on to insulin and metformin in type 2 diabetes (SWIM). Kesavadev J, Pillai P. B. S, Shankar A, Krishnan G, Jothydev S. Endocr Connect. 2017. 6(8). 748–757. Read More
  13. 13. The two levels of care for diabetes in a developing country: Mechanisms for improved intermediate health outcomes. Vitale R. J, Pillai P. B, Krishnan G, Jothydev S, Kesavadev J. Diabetes Metab Syndr. 2016. 10(1S1).S90-S94.
    Read More
  14. 14. CSII as an Alternative Therapeutic Strategy for Managing Type 2 Diabetes: Adding the Indian Experience to a Global Perspective. Kesavadev J, Shankar A, Pillai P. B. S, Saboo B, Joshi S, Krishnan G, Jothydev S. Curr Diabetes Rev. 2016. 12(4). 312-314. Read More
  15. 15. Fasting in Ramadan with an insulin pump. Kesavadev J. J Pak Med Assoc. 2015. 65(5S1). S47-50. Read More
  16. 16. Telemedicine for diabetes care: An Indian perspective - feasibility and efficacy. Kesavadev J, Saboo B, Shankar A, Krishnan G, Jothydev S. Indian J Endocrinol Metab. 2015. 19(6). 764–769. Read More
  17. 17. Liraglutide therapy beyond glycemic control: an observational study in Indian patients with type 2 diabetes in real world setting. Kesavadev J, Shankar A, Krishnan G, Jothydev S. Int J Gen Med. 2012. 5. 317-322. Read More
  18. 18. Cost-effective use of telemedicine and self-monitoring of blood glucose via Diabetes Tele Management System (DTMS) to achieve target glycosylated hemoglobin values without serious symptomatic hypoglycemia in 1,000 subjects with type 2 diabetes mellitus - a retrospective study. Kesavadev J, Shankar A, Pillai P. B. S, Krishnan G, Jothydev S. Diabetes Technol Ther. 2012. 14(9). 772-776. Read More
  19. 19. Suggested use of vaccines in diabetes. Kesavadev J, Misra A, Das A. K, Saboo B, Basu D, Thomas N, Joshi S. R, Unnikrishnan A. G, Shankar A, Krishnan G, Unnikrishnan R, Mohan V.Indian J Endocrinol Metab. 2012. 16(6). 886–893.
    Read More
  20. 20. An Asian Indian woman with Wolfram syndrome on insulin pump: successful pregnancy and beyond. Kesavadev J, Kumar A, Shankar A, Gopalakrishnan G, Permutt M. A, Wasson J, Jothydev S. Diabetes Technol Ther. 2011. 13(7). 781-785. Read More
  21. 21. Use of Insulin Pumps in India: Suggested Guidelines Based on Experience and Cultural Differences. Kesavadev J, Das A.K, Unnikrishnan R, Joshi S. R, Ramachandran A, Shamsudeen J, Krishnan G, Jothydev S, Mohan V. Diabetes Technol Ther. 2010. 12(10). 823–831. Read More
  22. 22. Reduction of glycosylated hemoglobin following 6 months of continuous subcutaneous insulin infusion in an Indian population with type 2 diabetes. Kesavadev J, Balakrishnan S, Ahammed S, Jothydev S. Diabetes Technol Ther. 2009. 11(8). 517-521. Read More
  23. 23. Gatifloxacin induced abnormalities in glucose homeostasis in a patient on glimepiride. Kesavadev J, Rasheed SA. J Assoc Physicians India. 2006 Dec;54:951-2. Read More
  24. 24. Diabetes in old age: an emerging epidemic. Kesavadev JD, Short KR, Nair KS. J Assoc Physicians India. 2003 Nov;51:1083-94. Read More
  25. 25. Early insulin initiation in T2DM is associated with prevention of eGFR decline and lower insulin dose requirements. Kesavadev J, Warrier R, Shankar A, David A, Ajai N. A, Sanal G, Thampiraj K, Ramachandran L, Krishnan G, Jothydev S.Diabetes. 2019. 68 (S1). 530-P. Link 1| Link 2
  26. 26. Improving the Quality of Life of T1DM Patients in a Community: A KT1DP Initiative. Kesavadev J, Saboo B. D, Shankar A, David A, Warrier R, Ajai N. A, Sanal G, Thampiraj K, Ramachandran L, Krishnan G, Jothydev S. Diabetes. 2019. 68 (S1). 2259-PUB. Read More
  27. 27. Consistency and Predictability of Control of Glycemic Variability with U200 (Concentrated r-DNA Human Insulin Premix 30/70-200 IU/mL) in Type 2 Diabetes Mellitus Patients. Thacker H, Kesavadev J, Ingole S. A, Shah A, Jain R. Diabetes. 2019. 68(S1). 2322-PUB. Read More
  28. 28. Harnessing the Power of Social Media for a Structured and Instant Intervention, Education and Counselling in Type 1 Diabetes. Kesavadev J, Shankar A, David A, Sanal G, Ajith J, Krishnan G, Ramachandran L, Jothydev S. Diabetes Technol Ther. 2019. 21. A116. Link 1 | Link 2 | Link 3
  29. 29. Assessing the Benefits of a Painless Lancing Device in a Subset of Patients Fearful of Finger Pricking. Warrier R, Badarudeen S, Shankar A, Krishnan G, Ramachandran L, Thampiraj K, Jothydev S, Kesavadev J. Diabetes Technol Ther. 2019. 21. A60-A61. Link 1 | Link 2 | Link 3
  30. 30. Patient and caregiver feedback on the first generation Artificial Pancreas in India. Kesavadev J, Ramachandran L, Shankar A, David A, Jose R, Anilkumar A L, Krishnan G, Jothydev S. Diabetes Technol Ther. 2018. 20(S1). A55-A56.
    Link 1 | Link 2
  31. 31. Utility of a multi-model bot enabled, and doctor led intervention for diabetes management- clinician and patient perspectives. Kesavadev J, Saboo B, Ramachandran L, Shankar A, David A, Krishnan G, Jothydev S. Diabetes Technol Ther.2018. 20(S1).A39- A40. Link 1 | Link 2
  32. 32. Diabetes duration-based initiation of insulin: impact on clinical outcomes, insulin dosage and quality of life. Kesavadev J, Saboo B, Shankar A, Jothydev K, Ramachandran L, Krishnan G, Jothydev S. Diabetes Technol Ther. 2018. 20(S1). A149- A150. Link 1 | Link 2
  33. 33. Effectiveness of a digital therapeutic for improving outcomes in South Asians living with type-2 diabetes - results from an ongoing real-world pilot trial. Saboo B, Shaikh M, Shah A, Sosale A, Kesavadev J, Chawla M, Makkar B M, Kovil R, Chawla R, Bajaj S. Diabetes Technol Ther. 2018. 20(S1). A79-A80. Read More
  34. 34. Are Complications Preventable with Periodic Education via Telemedicine? A Study of 414 Compliant T2D Patients Followed Up for 19 Years. Kesavadev J, Shankar A, David A, Krishnan G, Ajai N. A, Sanal G, Ajith J, Jayanthi S, Ramachandran L, Jothydev S.Diabetes. 2018. 67 (S1). 685-P. Link 1 | Link 2 | Link 3
  35. 35. Real-World Effectiveness of a Digital Therapeutic in Improving Glycaemic Control in South Asians Living with Type 2 Diabetes. Sosale A. R, Sr., Shaikh M, Shah A, Chawla R, Makkar B. M, Kesavadev J, Joshi S, Deshpande N, Agarwal S, Maheshwari A, Madhu S, Saboo B. D. Diabetes 2018 Jun, 61 (Supplement 1) 866-P; DOI: 10.2337/db12- 866-P. Read More
  36. 36. Patterns of Glycemic variability (GV) in Indian Type 2 diabetes (T2DM) patients on Insulin and Oral Hypoglycemic Agents (OHAs) and its Correlation with A1c and Hypoglycemia. Kesavadev J, Pillai P. B. S, Shankar A, Sanal G, Lally J, Gopalakrishnan G, JothydevS.Diabetes 2012 Jun, 61 (Supplement 1) 2343-PO; DOI: 10.2337/db12- 2343-PO. Read More
  37. 37. IDegAsp Improves Glycemic Control with Minimal Hypoglycemia - An Indian Real-World Study in T2D Subjects. Kesavadev J, Saboo B. D, Shankar A, David A, Warrier R, Krishnan NG, Ramachandran L, Jothydev S.Diabetes. 2018. 67(S1). 389-P. Link 1 | Link 2 | Link 3 | Link 4
  38. 38. One-Year Safety and Effectiveness of Insulin Degludec in Patients with Diabetes Mellitus in Routine Clinical Practice in India - TRUST (Tresiba Real-World Use Study). Kesavadev J, Murthy L. S, Saboo B. D, Yalamanchi S. R, Ramanathan B, Gupta S, Chatterjee S, Revanna M, Kasetty H. Diabetes. 2018. 67(S1). 1019-P. Link 1 | Link 2
  39. 39. Is Cancer Screening in Diabetes Justified? Insights from Electronic Medical Records. Kesavadev J, Shankar A, Ramachandran L, Krishnan G, Jothydev S. Diabetes Technol Ther.2017. 19(S1). A1-A133. Read More
  40. 40. Better Outcomes in Type 2 Diabetes Management with a User Friendly Flash Glucose Monitoring System: Freestyle Libre Pro. Kesavadev J, Krishnan G, Saboo B, Shankar A, Ashok AD, Sanal G, Ramachandran L, Jothydev S. Diabetes Technol Ther. 2017. 19(S1).A1-A133. Read More
  41. 41. Halting CKD Progression in Diabetes with Virtual Interactions- a 5 year Retrospective Analysis. Kesavadev J, Shankar A, Sanal G, Ramachandran L, Krishnan G, Jothydev S. Diabetes. 2017. 66(S1). A596- A597. 2282- PUB. Read More
  42. 42. Validation for Artificial Intelligence Leveraging Patient-Centric User Experience for Behavior Change in Subjects with Type 2 Diabetes. Aravind S. R, Saboo B. D, Shah T, Joshi S. S, Shaikh M, Subnis U, Shah A, Kesavadev J. Diabetes. 2017. 66(S1). 367 OR. Link 1 | Link 2 | Link 3
  43. 43. Sharing the Outcomes and User Experience from India in The First 750 Type 2 Diabetes Patients with the New Libre Pro 14-Day Glucose Sensor. Kesavadev J, Ramachandran L, Shankar A, David A, Krishnan G, Srinivas S, Ajai A, Sanal G, Jothydev S. Diabetes. 2017. 66(S1). LB27-LB28. Link 1 | Link 2 | Link 3
  44. 44. The significance of repeated education in correcting insulin injection techniques and improving glycemic control. Kesavadev J, David A, Shankar A, Sowmya J, Ramachandran L, Krishnan G , Jothydev S. Diabetes. 2017. 66 (S). A185-A186. 716-P. Link 1 | Link 2 | Link 3
  45. 45. Assessing the Therapeutic Utility of Professional Continuous Glucose Monitoring in Type 2 Diabetes Across Various Therapies: A Retrospective Evaluation. Kesavadev J, Vigersky R, Shin J, Pillai P. B. S, Shankar A, Sanal G, Krishnan G, Jothydev S. Adv Ther. 2017. 34(8). 1918-1927. Read More
  46. 46. Glucose monitoring technologies - Complementary or competitive? Role of Continuous Glucose Monitoring versus flash glucose monitoring versus self-monitoring of blood glucose. Kesavadev J, Ramachandran L, Krishnan G. J Diabetol. 2017. 8(3). 61-67. Review. Read More
  47. 47. Periodic follow up with telemanagement system for 15 years and significant reduction in vascular complications in T2DM. Kesavadev J, Shankar A, Krishnan G, Jothydev S. Diabetes Technol Ther. 2016. 18(S1). A92-A-93.
    Link 1 | Link 2 | Link 3
  48. 48. Comparing IPRO with Libre for Sensor Accuracy and User Friendliness. Kesavadev J, Shankar A, Sanal G, Krishnan G, Jothydev S, Pillai P. B. Diabetes Technol Ther. 2016. 18(S1). A74. Link 1 | Link 2 | Link 3
  49. 49. Extending Metformin Benefits in Patients with Type 2 Diabetes through Pill Technology: A Systematic Review of Nine Pooled Clinical Trials. Kumar S, Gupta S, Kumar A, Tiwaskar M, Sharma S, Kesavadev J, Thacker H, Wadhwa N, editors. Diabetes Technol Ther. 2016. 18(S1). A130-A131. Link 1 | Link 2
  50. 50. Comparison of the New Factory Calibrated Sensor with Existing CGM Sensor. Kesavadev J, Pillai P. B. S, Shankar A, Ashok A.D, Sanal G, Iyer R, Krishnan G, Jothydev S. Diabetes. 2016. 65(S1). A230.P896. Link 1 | Link 2 | Link 3
  51. 51. How Successful is Lifestyle Advice in Preventing the Progression of Prediabetes to Diabetes? Kesavadev J, Shankar A, Pillai P. B. S, Lally J, Krishnan G, Sanal G, Jothydev S.. Diabetes. 2016. 65(S1). A186-A187. P724. Link 1 | Link 2 | Link 3
  52. 52. Insulin pump therapy in pregnancy. Kesavadev J. J Pak Med Assoc. 2016. 66(9S1). S39-44.Review. Read More
  53. 53. Role of Home Blood Pressure Monitoring in Halting the Progression of Diabetic Kidney Disease: 6 Year Follow up Data. Kesavadev J, Joshi S, Saboo B, Shankar A, Pillai P. S, Sanal G, Jothydev S. Diabetes Technol Ther. 2015. 17. A123.
    Read More
  54. 54. Impact of Insulin Pump Therapy on Erectile Dysfunction in Type 2 Diabetes. Kesavadev J, Pillai P. S, Shankar A, Jothydev S. Diabetes Technol Ther. 2015. 17. A40. Read More
  55. 55. Telemedicine for diabetes care: An Indian perspective - feasibility and efficacy. Kesavadev J, Saboo B, Shankar A, Krishnan G, Jothydev S. Indian J Endocrinol Metab. 2015. 19(6). 764-769. Read More
  56. 56. Efficacy and safety of liraglutide therapy in 195 Indian patients with type 2 diabetes in real world setting. Kesavadev J, Shankar A, Gopalakrishnan G, Jothydev S.Diabetes Metab Syndr. 2015. 9(1). 30-33. Read More
  57. 57. Exploring and resolving the impact of food on post prandial glycemic excursions in a rice-eating population in S. India. Kesavadev J, Shankar A, Sanal G, Ajai N. A, Krishnan G, Jothydev S. Diabetes. 2015. 64(S1). 2486-PO. Link 1 | Link 2
  58. 58. Periodic CGM in T2DM: exploring benefits across various therapy choices. Kesavadev J, Pillai P. B. S, Shankar A, Sanal G, Lally J, Krishnan G, Jothyedv S. Diabetes. 2015. 64(S1). A244. P964. Link 1 | Link 2
  59. 59. Insulin-sparing effect of and Severe Hypoglycemia with Sitagliptin vs. Glimepiride. Kesavadev J, Pillai P. B. S, Shankar A, Krishnan G, Jothydev S. Diabetes. 2015. 64(S1). A604. PO2486. Read More
  60. 60. Comparing two models of diabetes care comprehensive education and telemonitoring vs. limited care. Kesavadev J, Vitale R, Babu P, Pillai S, Krishnan G, Jothydev S. Diabetes. 2015. 64(S1). A187- A188. P743. Link 1 | Link 2 | Link 3
  61. 61. Use of Insulin Pumps in T2DM in India: Merits and Demerits learnt over a decade. Kesavadev J. O-86. Diabetes Technol Ther. 2014 Feb. 16(S1): A-1–A-162. Read More
  62. 62. Clinical utility of CGM in pre-diabetes and its impact on modifying lifestyles. Kesavadev J, Shankar A, Sanal G, Lally J, Krishnan G, Jothydev S. Diabetes Technol Ther. 2014. 16. A41. P-106.Diabetes Technol Ther. 2014 Feb; 16(S1): A-1–A-162.
    Link 1 | Link 2
  63. 63. Live brief weekly educational questionnaire via DTMS® as a tool to improve the acceptability and outcome in type 2 diabetes. Kesavadev J, Shankar A, Sanal G, Lally J, Krishnan G, Jothydev S. Diabetes Technol Ther. 2014 Feb. 16(S1). A115-A116. P- 295. Read More
  64. 64. Use of Ipro2 in Real-Life Management of Type 2 Diabetes Patients In India. Mohan V, Kesavadev J, Jain S. M, Chawla M, Mutha A, Saboo B, Kovil R, Viswanathan V, Mithal A Punatar D, Shaikh, S, Shin J. P-311. Diabetes Technol Ther. 2014. 16(S1): A-1–A-162. Read More
  65. 65. Prevalence of undetected thyroid disorders in subjects with diabetes in South India: a cohort analysis. Krishnan G, Shankar A, Jothydev S, Kesavadev J. Diabetologia. 2014. 57(Sl). 1-564. Link 1| Link 2| Link 3
  66. 66. Challenges in Type 1 diabetes management in South East Asia: Descriptive situational assessment. Kesavadev J, Sadikot S. M, Saboo B, Shrestha D, Jawad F, Azad K, Wijesuriya M. A, Latt T. S, Kalra S. Indian J Endocrinol Metab. 2014. 18(5). 600–607. Read More
  67. 67. Consensus guidelines for glycemic monitoring in type 1/type 2 & GDM. Kesavadev J, Sadikot S. M, Wangnoo S, Kannampilly J, Saboo B, Aravind S. R, Kalra S, Makkar B. M, Maji D, Saikia M, Anjana R. M, Rajput R, Singh S. K, Shah S, Dhruv U, Vishwanathan V. Diabetes Metab Syndr. 2014. 8(3). 187-195. Read More
  68. 68. Continuous Glucose Monitoring in 432 T2D Patients for Assessment of Safety and Cost effectiveness in Reaching A1C Targets. Kesavadev J, Shankar A, Lally J, Sanal G, Gopalakrishnan G, Jothydev S. Diabetes. 2014. 63. A105. P398.
    Link 1| Link 2| Link 3| Link 4
  69. 69. Attitudes and Behaviour Of Type 2 Diabetes Patients on Insulin Pumps. Kesavadev J, Shankar A, Krishnan G, Jothydev S. Diabetes Technol Ther. 2013. 15(S1). A43- A44. Link 1 | Link 2 | Link 3
  70. 70. Glycemic Variability in Type 2 Diabetes Correlates with Total Daily Dose of Insulin And Use of Sulfonlyureas. Kesavadev J, Pillai P. B. S, Shankar A, Krishnan G, Jothydev S. Diabetes Technol Ther. 2013. 15(S1). A-66
    Link 1 | Link 2 | Link 3
  71. 71. Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Trivandrum cohort of the A1chieve study. Kesavadev J. Indian J Endocrinol Metab. 2013. 17(S2). S565–S568. Read More
  72. 72. Time of Insulin Initiation, Duration of disease and onset of Erectile Dysfunction in Indian men with T2D. Shankar A, Jothydev S, Gopalakrishnan G, Lally J, Kesavadev J. Diabetes. 2013. 62. A697. PO2737. Link 1 | Link 2
  73. 73. Long Term Impact of Initial Insulin Therapy in New Onset T2D: 5 year Retrospective Data. Kesavadev J, Shankar A, Gopalakrishnan G, Jothydev S.Diabetes. 2013. 62. A648. PO2552. Link 1 | Link 2
  74. 74. Normal Vitamin D Levels Correlates with Lower HbA1c: A Cross Sectional Study Among 1270 Type 2 Diabetes Patients in South India. Gopalakrishnan G, Pillai P. B. S, Shankar A, Jothydev S, Kesavadev J. Diabetes. 2013. 62. A703-A704. PO2763. Link 1 | Link 2
  75. 75. Superiority of a Telemedicine Based Counselling in Ensuring Multi Drug Compliance in T2D. Kesavadev J, Shankar A, Gopalakrishnan G, Lally J, Sanal G, Jothydev S.Diabetes.2013. 62. A176.698-P. Link 1 | Link 2 | Link 3
  76. 76. Improvement of glycemic control with addition of insulin detemir to existing antidiabetic therapy: a sub-group analysis of A1chieve observational study. Kesavadev J, Joshi S. R. J Assoc Physicians India. 2013. 61(S1). 28-30. Read More
  77. 77. C-peptide levels not affected by duration of diabetes in a telemedicine based long-term follow up programme. Krishnan G, Pillai P. S, Shankar A, Jothydev S, Kesavadev J.Diabetologia.2013. 56(S1). 1-566. Link 1 | Link 2
  78. 78. Efficacy and Safety of Liraglutide in 195 Patients with Type 2 Diabetes in India: A Retrospective Analysis. Kesavadev J, Shankar A, Gopalakrishnan G, Veeresh B, Jothydev S.Diabetes. 2012. 61(S1). 2403-PO. Read More
  79. 79. High Bed Time Glucose and Early Morning Low Sugars in Elderly Subjects with Type 2 Diabetes (T2DM): An Incidental Finding with Clinical Significance. Kesavadev J, Shankar A, Lally J, Sanal G, Gopalakrishnan G, Jothydev S. Diabetes 2012 Jun, 61 (Supplement 1) 881-P; DOI: 10.2337/db12- 881-P. Link 1| Link 2
  80. 80. Optimal statin dosages and compliance: a five year retrospective cohort analysis in South Indian type 2 diabetes subjects. Krishnan G, Pillai P. S, Shankar A, Kesavadev J, Jothydev S.Diabetologia.2012. 55 (S1). S7-537. Link 1 | Link 2
  81. 81. Acceptance of Continuous Glucose Monitoring (CGM) as a Routine Investigation in Diabetes. Kesavadev J, Pillai P. B. S, Shankar A, Gopalakrishnan G, Lally J, Sanal G, Jothydev S.Diabetes Technol Ther. 2012 Feb. 14(19). Read More
  82. 82. Geographical location and effectiveness of a simple telemedicine program (DTMS®) in diabetes. Kesavadev J, Pillai P. B. S, Shankar A, Gopalakrishnan G, Lally J, Jothydev S. Diabetes Technol Ther. 2012 Feb. 14(19). Read More
  83. 83. Continuous insulin infusion systems in type 2 diabetes. Kesavadev J. J Assoc Physicians India. 2011 Apr. 59(S). 41-43
    Read More
  84. 84. The usage of basal-plus regimen in the management of diabetes. Kesavadev J. Indian Journal of Clinical Practice (IJCP). Apr 2011.
  85. 85. A1c, BP and LDL Goals— Successful Use of Telemedicine (DTMS®) in 1000 Compliant T2DM Subjects over 6 Months. Kesavadev J, Babu P, Pillai S, Shankar A, Dinkar G, Lally J, Sanal G, Gopalakrishnan G, Jothydev S. Diabetes. 2011. 60(S1). 229- OR. Link 1 | Link 2
  86. 86. Significance of Screening for Thyroid Disorders in Type 2 Diabetes. Kesavadev J, Pillai P. B. S, Shankar A, Gopalakrishnan G, Jothydev S. Diabetes. 2011. 60(S1). P1377. Link 1 | Link 2
  87. 87. Utility of CGM over Conventional SMBG in Making Treatment Changes in Insulin Requiring T2DM Patients . Kesavadev J, Pillai P. B. S, Shankar A, Gopalakrishnan G, Sanal G, Lally J, Jothydev S. Diabetes. 2011. 60(S1). 912 P.
    Link 1 | Link 2
  88. 88. Change in Antihypertensive Medication Dose Following Initiation of Liraglutide in Patients. Kesavadev J, Shankar A, Gopalakrishnan G, Jothydev S. Diabetes. 2011. 60(S1) 2357-PO. Link 1 | Link 2
  89. 89. High Prevalence of Elevated Transaminases among T2DM in S.India. Kesavadev J, Shankar A, Pillai P. B. S, Suresh P, Gopalakrishnan G, Jothydev S. Diabetes. 2010. 59(S). A613-A614. 2340-PO. Read More
  90. 90. Telefollow up and SMBG Via “DTMS”- A Cost Effective Tool for A1c Lowering. Kesavadev J, Shankar A, Shamsudeen J, Dinkar G, Pillai B. S, Gopalakrishnan G, Ajai N, Sathish J, Jothydev S. Diabetes.2010. 59(S). A546. 2083-PO. Read More
  91. 91. A Clinician’s Perspective on Liraglutide in Clinical Practice. Tandon N, John M, Sharma S. K, Kesavadev J, Ganapathy B. J Assoc Physicians India, 2010. 58. 29-30. Read More
  92. 92. Role of Continuous Glucose Monitoring in Modifying Diet and Lifestyles in Diabetes subjects. Kesavadev J, Shamsudeen J, Badarudeen S, Jothydev S, Dinkar G. Oral Presentation, Speaker: Dr.Jothydev Kesavadev. Diabetes. 2009. 58(S1). 268-OR. Read More
  93. 93. Requirement of High Dosage of Insulin in Previous Users of Glibenclamide with Uncontrolled Diabetes. Kesavadev J, Shamsudeen J, Badarudeen S, Simon N. A, Jothydev S. Diabetes. 2009. 58(S1). PO2079. Read More
  94. 94. Indian Patients with Diabetes Experienced Better Glycemic Control, Less Weight Gain and Hypoglycaemia with Insulin Detemir When Switched from NPH and Insulin Glargine in PREDICTIVE™ Study. Kesavadev J, Singh P, Pitle S. U, Bhattacharyya A, Mayya R, Moharana A. K, Pathak A, Kalra S. Diabetes. 2009. 58 (S1). PO2053. Read More
  95. 95. Experiences with Insulin Pump in 52 Patients with Type 2 Diabetes in India. Kesavadev J, Kumar A, Ahammed S, Jothydev S.Diabetes. 2008. 57(S1). 2021-PO. Read More
  96. 96. Insulin Aspart Induced Lipoatrophy in a Patient on Insulin Pump. Kesavadev J, Kumar A, Ahammed S, Dinkar G, Jothydev S. Diabetes. 2008. 57(S1). 2093-PO. Read More
  97. 97. High Prevalence of Dyslipidemia and Hypertension Detected in a Screening Program for Diabetes in a Rural population of a Southern State in India, Kerala. Kumar A, Kesavadev J, Ahammed S, Dinkar G, Jothydev S. Diabetes. 2008. 57(S1). 2424-PO. Read More
  98. 98. A Study on the Effects of Acarbose in Reducing Post-Prandial Blood Glucose and Achieving HbA1c. Ahammed S, Kumar A, Gopi D. K, Kesavadev J. Diabetes. 2008. 57(S1). 438-P. Link 1 | Link 2
  99. 99. Achieving Desirable Glycemic Targets without the risks of Hypoglycemia using a Teletitration program. Kesavadev J, Rasheed S. A, Nair D. R. Diabetes. 2007. 56 (S1). 0421-P. Link 1 | Link 2
  100. 100. Dramatic Response of Painful Peripheral Neuropathy with Insulin Pump in Type2 Diabetes. Kesavadev J, Rasheed S. A. Diabetes. 2007. 56 (S1). 2097-PO. Read More
  101. 101. Consensus and recommendations on continuous glucose monitoring. Chawla M, Saboo B, Jha S, Bhandari S, Kumar P, Kesavadev J, Munjal YP, Mohan V, Unnikrishnan R, Katswar V, Arun N, Sosale B, Anjana RM, Hasnani D. J Diabetol. 2019. 10. 4-14. Read More
  102. 102. Consensus Statement on Use of Ambulatory Glucose Profile in Patients with Type 2 Diabetes Mellitus Receiving Oral Antidiabetic Drugs. Unnikrishnan AG, Saboo B, Joshi S, Kesavadev J, Makkar BM, Agarwal S, Aravind SR, Seshadri K, Chawla M, Deshpande N, Chawla R, Tiwaskar M. J Assoc Physicians India. 2019. 67(11). 76-83. Read More
  103. 103. Recommendations for in-clinic PoCT for diabetes management in India. Saboo B, Sadikot S, Prasanna Kumar KM, Joshi S, Aravind SR, Makkar BM, Chawla R, Kesavadev J, Chawla M, Kovil R, Shah T, Mohit M, Vyas C, Dhandhania VK. Diabetes Metab Syndr. 2019. 13(1). 5-7. Read More
  104. 104. Enabling Data-Driven Decision Making for Personalized Care in Type 2 Diabetes with Clinical and Lifestyle Journey Data Using a Digital Therapeutic. Chawla R, Shaikh M, Shah A, Saboo B. D, Makkar B. M, Kesavadev J, Joshi S, Deshpande N, Agarwal S, Maheshwari A, Sosale A. Madhu S. V. Diabetes.2018. 67(S1). 248-OR. Link 1 | Link 2
  105. 105. Efficacy of a Basal-Plus Regimen. Saboo B. D. J, Hasnani D, Chandarana H, Bhandari S, Joshi S, Kesavadev J, Maheshwari A, Thacker H. Diabetes. 2018. 67(1). 2292-PUB. Link 1 | Link 2
  106. 106. Conversational Artificial Intelligence for Achieving Activity Targets through Routine Physical Activity—Longitudinal Observational Study among People with Type 2 Diabetes. Makkar B. M, Shaikh M, Shah A, Joshi S, Saboo B. D, Sosale A. R, Madhu S. V, Kovil R, Shah T, Chawla M. S, Chawla R, Kesavadev J. Diabetes. 2018. 67(S1). 750-P.
    Link 1 | Link 2 | Link 3
  107. 107. Continuous Glucose Monitoring Guided Assessment of Concentrated U200 r-DNA Human Premix 30/70 Insulin. Thacker H, Kesavadev J, Singh G, Shukla K, Puppalwar G,Shrimanker R.Diabetes. 2018. 67(S1). 1013-P. Link 1 | Link 2 | Link 3
  108. 108. Sodium-glucose Cotransporter-2 Inhibitors in Combination with Other Glucose-lowering Agents for the Treatment of Type 2 Diabetes Mellitus. Kalra S, Kesavadev J,Chadha M, Kumar G. V. Indian J Endocrinol Metab. 2018. 22(6). 827–836. Read More
  109. 109. The JADE Collaborative Study Group. Cross‐sectional survey of biosimilar insulin utilization in Asia: The Joint Asia Diabetes Evaluation Program. Gani L, Lau E, Luk A, Sobrepena L, Tran Q. K, Kesavadev J, Jia W, Yu W, Tsang C. C, Mukhopadhyay M, Jha S, Sheu W, Ho Y. K, Nguyen T. N, Ozaki R, So W. Y, Kwan C, Fu A. W. C, Mirasol R, Phatak S. R, Kumar K. M. P, Aravind S, Janakiraman H, Chan J. C. N. J Diabetes Investig. 2018. 9(6). 1312–1322. Read More
  110. 110. Use of Ambulatory Glucose Profile for Improving Monitoring and Management of T2DM. Saboo B, Sheth SV, Joshi S, Bhandari S, Kesavadev J, Maheshwari A, Agrawal M, Hasnani D, Patel F, Panchal D, Goklani R. J Assoc Physicians India. 2018. 66(7).69-71. Read More
  111. 111. A Multicenter Real-Life Study on the Effect of Flash Glucose Monitoring on Glycemic Control in Patients with Type 1 and /7Type 2 Diabetes. Anjana R. M, Kesavadev J, Neeta D, Tiwaskar M, Pradeepa R, Jebarani S, Thangamani S, Sastry N. G, Kumar B. S, Ramu M, Gupta P. P. K, Vignesh J, Chandru S, Kayalvizhi S, Jagdish P. S, Uthra S. C. B, Lovelena M, Jyoti S, Priya S. S, Kannan A, Mohan V, Unnikrishnan R. Diabetes Technol Ther. 2017. 19(9). 533-540. Read More
  112. 112. Efficacy of Teneliglitpin as Monitored with Continous Glucose Monitoring System (CGMS) In Comparison with Standard of Care in Indian Setting. Thacker H, Kesavadev J, Shrimanker R.Official Journal Of The American Association Of Clinical Endocrinologists And The American College Of Endocrinology 2017. 23.60. A-257. Read More
  113. 113. Forum for Injection Technique and Therapy Expert Recommendations, India: The Indian Recommendations for Best Practice in Insulin Injection Technique, 2017. Tandon N, Kalra S, Balhara Y. P. S, Baruah M. P, Chadha M, Chandalia H. M, Kumar K. M. P, Madhu S. V, Mithal A, Sahay R, Shukla R, Sundaram A, Unnikrishnan A. G, Saboo B, Gupta V, Chowdhury S, Kesavadev J, Wangnoo S. K. Indian J Endocrinol Metab. 2017. 21(4). 600–617. Read More
  114. 114. Clinical practice points for diabetes management during RAMADAN fast. Sadikot S. M, Jothydev K, Zargar A. H, Ahmad J, Arvind S. R, Saboo B. Diabetes Metab Syndr. 2017. 11(S2). S811-S819. Read More
  115. 115. Evidence-based recommendations for insulin intensification strategies after basal insulin in type 2 diabetes. Ghosh S, Unnikrishnan A. G, Saboo B, Kesavadev J, Aravind S. R, Bajaj S, Rajput R, Seshadri K, Verma N, Gupta A, Makkar B. M, Saikia M, Kale S, Damodaran S, Dengra A, Eashwar T. K. M, Maheshwari A, Pendsey S, Phatak S. R, Sharma S. K, Singh S. K, Ramachandran A, Zargar A. H, Joshi S. R, Sadikot S. M. Diabetes Metab Syndr. 2017. 11(S1). S507-S521. Read More
  116. 116. Consensus on Initiation and Intensification of Premix Insulin in Type 2 Diabetes Management. Mohan V, Kalra S, Kesavadev J, Singh A. K, Kumar A, Unnikrishnan A. G, Chawla R, Mukherjee JJ, Sahay R. K, Kumar J. S, Bhoraskar A, Asirvatham A. J, Panda J. K, Zargar A. H, Das A. K. J Assoc Physicians India. 2017. 65(4). 59-73. Read More
  117. 117. Consensus on Insulin Dose and Titration Algorithms in Ambulatory Care of Type 2 Diabetes in India. Kovil R, Chawla M, Rajput R, Singh A. K, Sinha B, Ghosal S, Ballani P, Gupta S, Tanna S, Bandukwala S. M, Shah T, Negalur V, Bhoraskar A, Aravind S. R, Zargar A. H, Kesavadev J, Das A. K. J Assoc Physicians India. 2017. 65(2). 17-30. Read More
  118. 118. Platelet Proteins From Diabetic Subjects Cause Phenotypic Changes In Endothelial Cells In-Vitro. Hilary S, Shahna S, Kesavadev J ,Bhatt A. International Journal Of Life Science And Pharma Research. 2017. 7(1). 61-71. Read More
  119. 119. Use of Flash Glucose Monitor to Optimize the Dose of Basal Insulin Glargine–Real-World Clinical Data. Patel F, Goklani R, Saboo B, Hasnani D, Maheshwari A, Kesavadev J, Joshi S. R. Diabetes. 2017. 66(S1). A242. 939-P. Link 1 | Link 2
  120. 120. Use of Retrospective Continuous Glucose Monitoring for Optimizing Management of Type 2 Diabetes in India. Mohan V, Jain S, Kesavadev J, Chawla M, Mutha A, Viswanathan V, Saboo B, Kovil R, Mithal A, Punatar D, Shin J. J Assoc Physicians India. 2016. 64(4). 16-21. Read More
  121. 121. Liraglutide and Renal Outcomes in Type 2 Diabetes. Mann J. F. E , Ørsted D. D , Frandsen K. B, Marso S. P, Poulter N.R, Rasmussen S , Tornøe K, Zinman B , Buse J. B , LEADER Steering Committee and Investigators. N Engl J Med. 2017 Aug 31;377 (9):839-848. Link 1| Link 2
  122. 122. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. Marso S. P , Daniels G. H , Frandsen K. B , Kristensen P , Mann J. F. E , Nauck M. A , Nissen S. E , Pocock S , Poulter N. R , Ravn L. S , Steinberg W. M , Stockner M , Zinman B, Bergenstal R.M, Buse J. B , LEADER Steering Committee; LEADER Trial Investigators. N Engl J Med. 2016 Jul 28;375(4):311-22. Link 1| Link 2
  123. 123. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. Green J B, Bethel M. A, Armstrong P.W, Buse J. B, Engel S. S, Garg J, Josse R,Kaufman K. D, Koglin J, Korn S, Lachin J. M, McGuire D. K, Pencina M. J, Standl E, Stein P.P, Suryawanshi S, Werf F.V de, Peterson E. D, Holman R. R, TECOS Study Group. N Engl J Med. 2015 Jul 16;373(3):232-42.
    Link 1| Link 2
  124. 124. Forum for Injection Technique (FIT), India: The Indian recommendations 2.0, for best practice in Insulin Injection Technique, 2015. Tandon N, Kalra S, Balhara Y. P. S, Baruah M. P, Chadha M,Chandalia H. B, Chowdhury S, Jothydev K, Kumar P. K. M, Madhu S. V, Mithal A, Modi S, Pitale S, Sahay R, Shukla R, Sundaram A, Unnikrishnan A. G, Wangnoo S. K. Indian J Endocrinol Metab. 2015. 19(3). 317–331. Read More
  125. 125. Utilization of Biosimilar insulin in Asian patients with diabetes – The Joint Asia Diabetes Evaluation (JADE) program. Gani L. U, Lau E, Luk A, Sobrepena L, Tran Q. K, Kesavadev J, Jia W, Chan J. C. N. Diabetes. 2015. 64(S1). A262. P1023.
    Link 1 | Link 2
  126. 126. Consensus Statement on Management of Post-Prandial Hyperglycemia in Clinical Practice in India. Aravind S, Saboo B, Sadikot S, Shah S. N, Makkar B, Kalra S, Kannampilly J, Kesavadev J, Ghoshal S, Zargar A, Nigam A, Hazra D, Tripathi K, Dharmalingam M, Shah P, Gandhi P, Sahay R, Unnikrishnan R, Gupta S, Bajaj S, Mukhopadhyay S, Kale S. J Assoc Physicians India. 2015. 63(8). 45-58. Read More
  127. 127. Intensifying Insulin Therapy in Type 2 Diabetes: Choices & Challenges. Kumar A, Kesavadev J, Sethi B, Jain S. M, Guruprasad C. S, Shah S. N. J Assoc Physicians India. 2015. 63(5S). 8-14. Review. Read More
  128. 128. Understanding the safety of the new ultra long acting basal insulin. Ramachandran A, Gupta V, Kesavadev J, Kalra S. J Assoc Physicians India. 2014. 62(1S). 35-42. Read More
  129. 129. Addendum 2: Forum for Injection Technique, India. Kalra S, Balhara Y. P. S, Baruah M. P, Chadha M, Chandalia H. M, Chowdhury S, Kesavadev J, Kumar K. M. P, Modi S, Pitale S, Rishi S, Sahay R, Sundaram A, Unnikrishnan A. G, WangnooS. K. Indian J Endocrinol Metab. 2014. 18(6). 800–803. Read More
  130. 130. Addendum: First injection technique recommendations for patients with diabetes, Forum for Injection Techniques India. Kalra S, Balhara Y. P. S, Baruah M. P, Chadha M, Chandalia H. B, Chowdhury S, Kesavadev J, Kumar K. M. P, Modi S, Pitale S, Rishi S, Sahay R, Sundaram A, Unnikrishnan A. G, Wangnoo S. K. Indian J Endocrinol Metab. 2013. 17(6). 1005–1008. Read More
  131. 131. Barriers and solutions to diabetes management: An Indian perspective. Wangnoo S. K, Maji D, Das A. K, Rao P. V, Moses A, Sethi B, Unnikrishnan A. G, Kalra S, Bantwal V. B. G, Kesavadev J, Jain S. M, Dharmalingam M. Indian J Endocrinol Metab. 2013. 17(4). 594–601. Read More
 

Contact Us

Trivandrum

Jothydev's Diabetes & Research Centre, JDC Junction, Mudavanmugal, Konkalam, Trivandrum, Kerala, India.
Pin-695032

Kochi

Jothydev's Diabetes Research Centre & Hospitals Pvt Ltd,
Ist Floor, Thekkekkara Comercial Centre, Civil Lines Road, Padivattom, Edapally PO, Kochi, Kerala, India.
Pin - 682024

Attingal

Jothydev's Diabetes Hospital & Research Centre,
CSI Mission Hospital Campus, Attingal, Trivandrum, Kerala, India. Pin-695101.

toll free number : 1800-425-40055